Among these factors, IFN-γ in the tumor microenvironment (TME) affects both tumor and immune cells in both immunoactivating and immunosuppressive ways 13 which explains why that early approaches targeting IFN-γ in the TME largely failed to provide any clinical benefit 14-16. The gene discussed is IFNG; the disease is neoplasm.